glp 1 agonists names GLP-1 receptor and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits Patents and regulatory exclusivities on

mAbs 8 , 659671 (2016)

Current serotonin medications are aimed at increasing central 5-HT neurotransmission in the brain, and there are no approved indications for manipulating peripheral 5-HT, though peripheral 5-HT synthesis is being considered as a potential target for developing pharmacological agents in some disorders ( We are not aware of prior studies reporting low S-5-HT in hypothyroidism or CFS

Key points: In clinical trials, tirzepatide (Mounjaro) produced roughly double the average weight loss of liraglutide (Saxenda), though these were separate trials with different durations Tirzepatide at the 15 mg dose produced approximately 21% average weight loss over 72 weeks Liraglutide 3.0 mg produced approximately 8% average weight loss over 56 weeks Real-world data from Second Nature shows even greater results (22.1%) when tirzepatide is combined with behavioural support Side effects and tolerability Both medications share a similar side-effect profile, predominantly affecting the gastrointestinal tract

Lancet (2020) 395:12434

For weight loss indications, this usually means demonstrating at least a 5% reduction in total body weight

Dose adjustment of ACEI in patients treated with GLP1RAs is probably not required